Trials / Completed
CompletedNCT04290676
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 527 (actual)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Detailed description
This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DEXYCU (dexamethasone intraocular suspension) 9%. | DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone). |
Timeline
- Start date
- 2019-11-13
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
- First posted
- 2020-03-02
- Last updated
- 2021-05-26
- Results posted
- 2021-05-26
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04290676. Inclusion in this directory is not an endorsement.